Alpha TeknovaTKNO
Recorded

Alpha Teknova 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration44 minParticipants11

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hello, and welcome to Teknova third quarter 2026 financial results. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. I would now like to turn the call over to Jennifer Henry, Senior Vice President of Marketing.

Jennifer HenrySenior Vice President of Marketing

You may begin. Thank you, operator.

Jennifer HenrySenior Vice President of Marketing

Welcome to Teknova's third quarter 2026 earnings conference call. With me on today's call are Stephen Gunstream, Teknova's President and Chief Executive Officer, and Matt Lowell, Teknova's Chief Financial Officer, who will make prepared remarks and then take your questions. As a reminder, the forward-looking statements that we make during this call, including those regarding business goals and expectations for the financial performance of the company, are subject to risks and uncertainties that may cause actual events or results to differ. Additional information concerning these risk factors is included in the press release the company issued earlier today, and they are more fully described in the company's various filings with the SEC.

Jennifer HenrySenior Vice President of Marketing

Today's comments reflect the company's current views, which could change as a result of new information, future events, or other factors, and the company does not obligate or commit itself to update its forward-looking statements, except as required by law. The company's management believes that, in addition to GAAP results, non-GAAP financial measures can provide meaningful insight when evaluating the company's financial performance and the effectiveness of its business strategies. We will therefore use non-GAAP financial measures of certain of our results during this call. Reconciliations of GAAP to non-GAAP financial measures are included in the press release that we issued this afternoon, which is posted to Teknova's website and at www.sec.gov/edgar. Non-GAAP financial measures should always be considered only as a supplement to, and not as a substitute for or as superior to, financial measures prepared in accordance with GAAP.

Jennifer HenrySenior Vice President of Marketing

The non-GAAP financial measures in this presentation may differ from similarly named non-GAAP financial measures used by other companies. Please also be advised that the company has posted a supplemental slide deck to accompany today's prepared remarks. It can be accessed on the investor relations section of Teknova's website and on today's webcast. I will turn the call over to Steven.

Stephen GunstreamPresident and CEO

Thank you, Jen. Good afternoon, and thank you everyone for joining us for our third quarter 2026 earnings call. As you saw in the press release, we delivered our second consecutive quarter of record revenue, with 22% top-line growth compared to the same period last year. In addition to exceeding 20% growth for the first time in over four years, we are particularly encouraged that the growth came from sales of custom products to life science tools and diagnostics customers, and notably, to biopharma customers. We believe the recent acceleration of revenue growth from sales to biopharma customers is an early indication that we're benefiting from the increase in biotech funding that we've observed over the previous four quarters. Given this backdrop, we feel confident as we head into 2027. I'd like to start by providing more color about our revenue growth.

Stephen GunstreamPresident and CEO

First, as I mentioned, our above-market revenue growth is from sales of custom products. Catalog products, which were about 60% of revenue in 2025, have grown in the mid-single digits year to date. While sales to large pharma have grown in the mid-teens, total catalog growth was offset by headwinds from products sold into other biopharma end markets, like cell and gene therapy and contract manufacturing. We attribute that to the limited share of recent financings going toward early-stage programs and discovery work, but we expect that to change eventually if funding continues to increase. That said, this quarter, we saw a significant uptick in custom product purchases from biopharma customers, much of which were for programs already in clinical trials. The growth was broad-based across multiple accounts and therapeutic modalities.

Stephen GunstreamPresident and CEO

Combined with our direct conversations with customers regarding planned purchases in 2027, the data lead us to believe that this revenue growth is tied to the recent increase in biotech funding, which multiple sources report is up approximately 70% on a trailing 12-month basis. We also saw continued robust revenue growth from sales of custom products to tools and diagnostics customers, like in the first half of 2026, with notable demand from liquid biopsy and sequencing-related applications such as spatial biology. Internally, the organization is performing well. Year to date, the number of custom order line items increased by approximately 30%, and we've expanded our customer base by nearly 10%. Even with that growth, we've demonstrated our ability to scale without a significant increase in expenses.

Stephen GunstreamPresident and CEO

Apart from the planned $2 million annual increase in sales and marketing spend, operating expenses are flat year to date, and our gross margins expanded by about 400 basis points. We believe our costs will only increase modestly as the business continues to scale, which reflects the value of our previous investments in facilities, IT systems, and manufacturing infrastructure. We're also encouraged by the early traction of our two new launches, Build-Tek, our AI-powered custom configurator, and Fill-Tek, our new dispensing system. Since we introduced the new version of Build-Tek in June, customers from more than 100 organizations have submitted more than 140 quote requests, covering nearly 180 custom products. We're also seeing repeat use with more than 40% of October requests coming from returning customers. Just as important is the quality of that demand.

Stephen GunstreamPresident and CEO

Nearly every request is a unique formulation, and about a third are for RUO+ or GMP-grade products, the higher quality tiers customers typically need as programs move toward clinical and commercial manufacturing. Therefore, we believe Build-Tek is helping us capture custom demand earlier and positions us to grow with programs as they scale. On the manufacturing side, we introduced our Fill-Tek Dispensing System in September to meet the evolving needs of bioprocessing for emerging therapies. This unique system allows us to tailor our production of single-use bags to fit our customers' bioprocessing environments, including by combining a variety of bag sizes and aseptic connectors into a single lot and reducing the minimum order requirements, all with the same industry-leading turnaround times. Furthermore, by integrating more deeply into our customers' workflows, we believe they will be incentivized to remain a customer as they advance their therapies towards commercialization.

Stephen GunstreamPresident and CEO

This new capability is hitting the mark. We have already received many orders quoted through Fill-Tek, with more than 60% of them for GMP-grade products, reinforcing Fill-Tek's fit for scale-up into clinical and commercial manufacturing. I also want to touch on M&A. We remain focused on tuck-in acquisition opportunities that would allow us to leverage our facilities, systems, and manufacturing infrastructures. Alongside those characteristics, we're also looking for opportunities through which we could expand into manufacturing additional reagents, such as proteins. Any attractive target would need to help us grow our addressable market and further differentiate our business while leveraging the commercial channel we have built. At the same time, we're confident in our organic strategy and are in a good position to be disciplined when considering valuations and integration risks.

Stephen GunstreamPresident and CEO

In closing, as we look toward the end of 2026, I'm proud of the progress we've made on our growth strategy. Our customer pipeline is strong, the investments we made to scale are in place and working, and we are delivering operationally. I will now hand the call to Matt to walk through the financials.

Matt LowellCFO

Thanks, Stephen, and good afternoon, everyone. As Stephen explained, total revenue was up 22% for the third quarter of 2026 compared to the same quarter prior year. This was again the highest quarterly revenue the company has achieved in its history. We are very pleased with our progress on key profitability measures and cash usage as well. Overall, we delivered excellent financial results for the third quarter 2026. By way of reminder, we target our Lab Essentials products at the research-use-only, or RUO market, and they include both catalog and custom products. Lab Essentials revenue was $9 million in the third quarter 2026, up 9% compared to $8.3 million in the third quarter 2025. The increase in Lab Essentials revenue is attributable to an increased number of customers and, to a slightly lesser extent, higher average revenue per customer.

Matt LowellCFO

We make our Clinical Solutions products according to good manufacturing practices, or GMP quality standards, and our customers use them primarily as components or inputs in the development and manufacture of diagnostic and therapeutic products. Clinical Solutions revenue was $3.2 million in the third quarter 2026, an 86% increase from $1.7 million in the third quarter 2025. The increase in Clinical Solutions revenue was attributable to a higher average revenue per customer and, to a lesser extent, an increased number of customers. We expect revenue per customer to increase over time as a subset of these customers ramp up their purchase volumes as they move through clinical trial phases and ultimately to commercialization. However, this metric can be affected by the addition of newer Clinical Solutions or GMP catalog customers who typically order less.

Matt LowellCFO

Just as a reminder, due to the larger average order size in Clinical Solutions compared to Lab Essentials, there can be more quarter-to-quarter revenue lumpiness in this category. Gross profit for the third quarter 2026 was $4.8 million compared to $3.2 million in the third quarter 2025. Gross margin was 38.0% in the third quarter 2026, up from 30.7% in the third quarter 2025. The increase in gross profit percentage was primarily driven by higher revenue and, to a lesser extent, lower fixed cost absorption into cost of goods sold from changes in finished goods inventory levels, partially offset by higher variable manufacturing costs. Operating expenses for the third quarter 2026 were $8.0 million compared to $7.2 million in the third quarter 2025.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day